Table 1.
Patient characteristics in the discovery cohort
| Characteristics | No. (%) |
|---|---|
| Gender | |
| Male | 234 (60.6) |
| Female | 152 (39.4) |
| Age | |
| ≥ 60 | 157 (40.7) |
| < 60 | 229 (59.3) |
| Cancer type | |
| Non-small cell lung cancer | 129 (33.4) |
| Melanoma | 185 (47.9) |
| Clear cell renal cell carcinoma | 35 (9.1) |
| Bladder cancer | 27 (7.0) |
| Head and neck cancer | 10 (2.6) |
| Drug class | |
| CTLA-4 (mono) | 142 (36.8) |
| PD-(L)1 (mono) | 115 (29.8) |
| CTLA-4 + PD-(L)1 (combo) | 129 (33.4) |
| Best overall response | |
| CR/PR | 118 (30.6) |
| SD | 94 (24.4) |
| PD | 163 (42.2) |
| NEa | 11 (2.8) |
| Durable clinical benefit | |
| DCB | 163 (42.2) |
| NDB | 195 (50.5) |
| NEb | 28 (7.3) |
| EPHA7 status | |
| EPHA7-WT | 348 (90.2) |
| EPHA7-MUT | 38 (9.8) |
| Overall patients | 386 |
Abbreviations: CR complete response, CTLA-4 cytotoxic T cell lymphocyte-4, DCB durable clinical benefit, NDB no durable benefit, NE not evaluable, PD progressive disease, PD-(L)1 programmed cell death-1 or programmed death-ligand 1, PR partial response, SD stable disease
aEleven patients with best overall response not evaluable due to missing data, including four from Miao et al. [25] and seven from Hellmann et al. [27]
bTwenty-eight patients with durable clinical benefit not evaluable, including 11 missing data and 17 patients who had not progressed but were censored before 6 months of follow-up